Indaptus Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Indaptus Therapeutics, Inc. (INDP) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$953.81 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- Indaptus Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$7.01M.
- Indaptus Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$1.90M.
- Indaptus Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$3.62M.
- Indaptus Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$2.82M.
- Indaptus Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $2.72M.
- Indaptus Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$7.58M, a 302.81% decline from fiscal 2023.
- Indaptus Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $3.74M.
- Indaptus Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$29.51M, a 178.69% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$953.81K 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | -$7.01M 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | $2.72M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $38.89K 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $370.95K 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | -$1.90M 10-Q · filed 2026-05-15 | ||||
| 2024-12-31 | -$7.58M 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | -$5.98M 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | -$6.06M 10-Q · filed 2025-08-13 | ||||
| 2024-03-31 | -$3.62M 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | $3.74M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $6.34M 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | $3.07M 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | -$2.82M 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | -$29.51M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | -$32.41M 10-Q · filed 2023-11-06 | ||||
| 2022-06-30 | -$24.87M 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | -$5.92M 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $37.49M 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | $40.22M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $3.33M 10-Q · filed 2022-08-08 | $3.46M 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $2.85M 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | -$2.16M 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | -$1.20M 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $4.56M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |